Drug intelligence / Profile preview

bifidobacterium animalis lactis VES002 + fructo-oligosaccharides

Development stage
Unknown
Lead developer
Ceres Pharma
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This product is a **combination of a probiotic bacterial strain, bifidobacterium animalis lactis VES002, and fructo-oligosaccharides (FOS), a type of prebiotic.** Bifidobacterium animalis lactis VES002 is a proprietary probiotic strain used to help maintain or restore healthy intestinal microflora, particularly **intestinal barrier integrity and mucosal immunity**. It acts primarily through modulation of the gut microbiome, enhancement of IgA secretion, and restoration of tight junction proteins, potentially via activation of Toll-like receptor 2 (TLR2) pathways. Fructooligosaccharides function as prebiotics, selectively stimulating the growth of beneficial gut bacteria such as bifidobacteria and lactobacilli. This combination is typically formulated as a dietary supplement to improve or support digestive health and immune modulation in humans, particularly in cases of intestinal dysbiosis, antibiotic use, or compromised gut barrier[1][3][4]. Developers often conduct strain-specific research, so the VES002 designation suggests a proprietary variant, distinct from common reference strains such as BB-12 or HY8002. While there is robust evidence for combinations of Bifidobacterium animalis lactis strains and FOS, explicit published data on VES002 is limited; the product's expected effects and mechanisms are inferred from related strains[1][3][4].

Other names
bifidobacterium animalis lactis VES002 and fructooligosaccharides
02

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on bifidobacterium animalis lactis VES002 + fructo-oligosaccharides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis lactis VES002 + fructo-oligosaccharides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call